Teva, Mylan, Other Generic Makers Hit With Price-Fixing Suit

Law360 (October 11, 2019, 10:25 PM EDT) -- UnitedHealthcare on Friday accused Teva, Mylan and more than a dozen other generic-drug makers of an egregious price-fixing scheme, claiming executives divvied up market share over fine Scotch and inflated the prices of more than 100 drugs, costing patients and insurers billions.

The sprawling lawsuit in Minnesota federal court is less a complaint against individual companies than a broadside against the entire industry, alleging that collusion between ostensible competitors was so ingrained it spawned its own lexicon and culture of double-dealing, transmitted through coded language and between rounds of golf, and lavish dinners shared by high-level executives.

"Since at least in or...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS